| Literature DB >> 36211322 |
Ali A Al-Rajhi1,2, Enmar M Almazyad1.
Abstract
PURPOSE: To report the surgical outcome of early lens aspiration, posterior chamber intraocular lens (PC IOL), and capsular tension ring (CTR) in a case series of microspherophakia (MSP) and secondary glaucoma.Entities:
Keywords: Capsular tension ring; glaucoma; lens aspiration; lens-induced myopia; spherophakia
Year: 2022 PMID: 36211322 PMCID: PMC9535905 DOI: 10.4103/sjopt.sjopt_231_21
Source DB: PubMed Journal: Saudi J Ophthalmol ISSN: 1319-4534
Demographics and characteristics of microspherophakia cases (=18 eyes)
| Variable | Mean±SD | Minimum-maximum | Range | Median | Mode |
|---|---|---|---|---|---|
| Age (years) | 16.4±7.3 | 9-35 | 26 | 14.5 | 12 |
| Axial length (mm) | 21.9±1.2 | 20-24 | 4 | 21.7 | 20.8 |
| Lens thickness (mm)*,† | 4.43±0.47 | 4-5.18 | 1.18 | 4.21 | 4 |
| Preoperative ACD (mm)*,† | 1.4±0.6 | 0.3-2 | 1.8 | 1.6 | 0.3 |
| Preoperative (baseline) SE (D)† | −12.8±3.5 | −8-−20.6 | 12.6 | −11.8 | −14.5 |
| Preoperative (baseline) BCVA (LogMar) | 0.3±0.1 | 0.2-0.5 | 0.4 | 0.3 | 0.3 |
| Preoperative (baseline) IOP (mmHg)† | 21.7±9.5 | 8-40 | 32 | 19.5 | 12 |
| Duration of follow up (years) | 8.8±3.9 | 0.7-13.3 | 12.7 | 10.5 | 5 |
*Scheimpflug imaging (Pentacam HR; OCULUS Optikgerate, Wetzlar, Germany). † Missing data anterior chamber depth. BCVA: Best-corrected visual acuity, LogMar: Logarithm of the Minimum Angle of Resolution, IOP: Intraocular pressure, SE: Spherical equivalent, ACD: Anterior chamber depth, SD: Standard deviation
Preoperative and postoperative details of microspherophakia cases
| Case | Age (years) | Prior intervention | Lensectomy to glaucoma surgery (years) | Glaucoma surgery after lensectomy | BCVA preoperative* | BCVA postoperative* | SE preoperative | SE postoperative | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 22 | Yag PI | - | 20/70 | 20/30 | –19.6 | –2.00 | |||||
| 2 | 14 | Yag PI | 11 | CPC | 20/40 | 20/30 | –11.6 | –4.5 | ||||
| 3 | 14 | Yag PI | - | - | 20/30 | 20/25 | –11.75 | –4.00 | ||||
| 4 | 35 | Yag PI, CPC | - | - | 20/40 | 20/30 | – | –0.50 | ||||
| 5 | 35 | Yag PI | - | - | 20/40 | 20/25 | –8.00 | –0.25 | ||||
| 6 | 17 | Yag PI | - | - | 20/40 | 20/20 | –17.00 | –2.25 | ||||
| 7 | 17 | Yag PI | - | - | 20/40 | 20/20 | –14.00 | –2.50 | ||||
| 8 | 15 | Yag PI | - | - | 20/40 | 20/30 | –10.00 | –1.50 | ||||
| 9 | 15 | Yag PI | - | - | 20/40 | 20/30 | –10.00 | –1.00 | ||||
| 10 | 12 | Yag PI | 2 | Ahmad implant + pericardial patch, Then revision encapsulated bleb | 20/70 | 20/30 | –9.00 | –1.00 | ||||
| 11 | 12 | Yag PI | 1 | Ahmad implant + pericardial patch | 20/50 | 20/25 | –8.5 | –1.75 | ||||
| 12 | 11 | Yag PI | 1 | Ahmad valve implant | 20/50 | 20/20 | –10.5 | –2.00 | ||||
| 13 | 11 | Yag PI | 4 | Ahmad valve implant | 20/50 | 20/40 | –13.00 | –0.60 | ||||
| 14 | 17 | Yag PI | 1 | CPC | 20/30 | 20/40 | –10.75 | - | ||||
| 15 | 9 | Yag PI | - | - | 20/40 | 20/30 | –14.50 | - | ||||
| 16 | 9 | Yag PI | - | - | 20/40 | 20/25 | –14.50 | - | ||||
| 17 | 12 | Yag PI | - | - | 20/60 | 20/25 | –15.50 | + 2.00 | ||||
| 18 | 12 | Yag PI | - | - | 20/60 | 20/25 | –13.25 | + 0.12 | ||||
|
| ||||||||||||
|
|
|
|
| |||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
| ||||||||||||
| 1 | 17 | 16 | 13 | 15 | 18 | 21 | 11 | 11 | None | None | 0 | 0 |
| 2 | 24 | 19 | 22 | 24 | 23 | 29 | 20 | 16 | Xalatan | Lumigan | 1 | 1 |
| 3 | 21 | 17 | 15 | 14 | 16 | 12 | 15 | 15 | Xolamol | Timilol, Azopt | 2 | 2 |
| 4 | 40 | 8 | 25 | 15 | 19 | 12 | - | 13 | Alphagan Xolamol | None | 3 | 0 |
| 5 | 18 | - | - | - | 15 | 15 | - | 16 | Alphagan Xolamol | None | 3 | 0 |
| 6 | 23 | 20 | - | - | 19 | 26 | 19 | 22 | Xola | Xolamol | 1 | 2 |
| 7 | 18 | - | - | - | 19 | 22 | 19 | 20 | Xola | Xolamol | 1 | 2 |
| 8 | 15 | 18 | 15 | 16 | 12 | 16 | 17 | 17 | None | None | 0 | 0 |
| 9 | 14 | 15 | 13 | 15 | 13 | 13 | 13 | 15 | None | None | 0 | 0 |
| 10 | 12 | 14 | 18 | - | 46 | 16 | 22 | 22 | Maximum | Xolamol | 4 | 2 |
| 11 | 36 | 31 | 7.5 | 8 | 22 | 17 | 10 | 17 | Apraclonadine + Xolamol | Xolamol | 3 | 2 |
| 12 | 30 | - | - | - | 12 | 18 | 20 | 18 | Bromidine.Xolamol | Lumigan, Alphagan, Xolamol | 3 | 4 |
| 13 | 8 | - | - | - | 17 | 26 | 16 | 17 | Bromidine.Xolamol | Xolamol | 3 | 2 |
| 14 | 12 | - | - | - | 32 | - | - | 32 | Diamox, Timilol | None | 2 | 0 |
| 15 | - | - | - | - | - | - | - | - | None | None | 0 | 0 |
| 16 | - | - | - | - | - | - | - | - | None | None | 0 | 0 |
| 17 | 31 | - | - | - | 13 | 17 | - | 17 | Timilol, Alphagan | Betagan | 2 | 1 |
| 18 | 36 | - | - | - | 15 | 15 | - | 15 | Timilol, Alphagan, Truspot | Betagan | 3 | 1 |
*BCVA measured in Snellen chart. Yag PI: Peripheral iridotomy, CPC: Cyclophotocoagulation, BCVA: Best-corrected visual acuity, SE: Spherical equivalent, IOP: Intraocular pressure, AC: Anterior chamber, MMC: Mitomycin C
Best-corrected visual acuity and intraocular pressure obtained postoperatively during follow-up
| Variable | Mean±SD (minimum-maximum), range | |||||
|---|---|---|---|---|---|---|
| Preoperative (baseline) | 1 year† | 5 years† | 10 years† | Last follow up§ |
| |
| BCVA (LogMAR) | 0.3±0.1 (0.2-0.5), 0.4 | 0.3±0.2 (0-0.8), 0.8 | 0.2±0.2 (0-0.5), 0.5 | 0.2±0.1 (0-0.4), 0.4 | 0.2±0.2 (0-0.8), 0.8 | 0.006** |
| IOP (mmHg) | 21.7±9.5 (8-40), 32† | 18.9±8.3 (12-46), 34 | 18.4±5.2 (12-29), 17 | 16.3±3.8 (10-22), 12 | 17.3±4.7 (11-32), 21 | 0.131 |
*P value comparing last follow-up to baseline.**Statistically significant at 5% level of significance, §8.8±3.9 (0.7-13.3) years, † Missing data. BCVA: Best-corrected visual acuity, LogMar: Logarithm of the Minimum Angle of Resolution, IOP: Intraocular pressure, SD: Standard deviation
Figure 1Best-corrected visual acuity and intraocular pressure obtained postoperatively during follow-up
Figure 2Micropsherophakia with high myopia (a) and iris corneal touch with peripheral iridotomy in OD (b and c), OS (d) Preoperatively and deepening of anterior chamber, clear cornea with intraocular lens in good position in both eyes (e and f) postoperatively
Comparison between baseline and postoperative outcomes
| Study | Eyes | Preoperative (baseline) mean±SD (minimum–maximum) | |||||
|---|---|---|---|---|---|---|---|
| Age (years) | BCVA (LogMar) | IOP (mmHg) | SE (D) | ACD (mm) | Antiglaucoma medications | ||
| Current study (retrospective case-series) | 18 | 16.4±7.3 (9-35) | 0.3±0.1 (0.2-0.5) | 21.7±9.5 (8-40) | −12.8±3.5 (−8-−20.6) | 1.4±0.6 (0.3-2)§ | 1.8±1.3 (0-4) |
| Yang | 7* | 40.28±24.22 (13-67) | 0.79±0.36 (0.15-1.3) | 28.84±5.36 (20-36) | −11.85±3.71 (−7-−18) | 1.21±0.55** | 4.14±0.9 |
|
| |||||||
|
|
|
| |||||
|
|
|
|
|
|
| ||
|
| |||||||
| Current study (retrospective case-series) | 18 | 8.8±3.9 (0.7-13.3) | 0.2±0.2 (0-0.8) | 17.3±4.7 (11-32) | −1.5±1.6 (2-−4.5) | 3.3±0.5 (2.5-4.1)§ | 1.2±1.2 (0-4) |
| Yang | 7* | 3 | 0.44±0.38 | 15.86±0.79 | −1.25±0.78 | 3.16±0.52** | 0.71±0.49 |
*Compared to group 1 in the study (phacoemulsification + CTR + PC IOL), **Ultrasound biomicroscopy the AOD at 500 mm anterior to the scleral spur (AOD 500), §Scheimpflug imaging (Pentacam HR; OCULUS Optikgerate, Wetzlar, Germany). BCVA: Best-corrected visual acuity, LogMar: Logarithm of the Minimum Angle of Resolution, IOP: Intraocular pressure, SE: Spherical equivalent, ACD: Anterior chamber depth, CTR: Capsular tension ring, PC IOL: Posterior chamber intraocular lens, AOD Angle opening distance